Published in Alzheimers Res Ther on November 10, 2016
Knowledge, Attitudes and Beliefs About AD Among Latinos in NYC | NCT04471779
Recruiting to preclinical Alzheimer's disease clinical trials through registries. Alzheimers Dement (N Y) (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (2011) 29.14
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth (2012) 4.39
Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA (2002) 3.19
A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med (2008) 3.06
Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82
The A4 study: stopping AD before symptoms begin? Sci Transl Med (2014) 2.43
Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. Alzheimer Dis Assoc Disord (2008) 2.30
Patients-in-waiting: Living between sickness and health in the genomics era. J Health Soc Behav (2010) 2.07
Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol (2005) 2.03
Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood) (2005) 1.93
Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol (2011) 1.85
Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord (2003) 1.79
Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood) (2010) 1.67
Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist (2000) 1.33
Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns (2006) 1.26
Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr (2010) 1.25
Predictive genetic testing for Alzheimer's disease: impact upon risk perception. Risk Anal (2005) 1.25
"I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med (2010) 1.19
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol (2013) 1.17
Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet Med (2005) 1.17
Illness representations among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord (2001) 1.16
Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry (2014) 1.13
Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis (2009) 1.10
Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement (2008) 1.00
The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL Study. Eur J Hum Genet (2010) 0.98
Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc (2014) 0.93
Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry (2015) 0.90
Postgenomics, uncertain futures, and the familiarization of susceptibility genes. Soc Sci Med (2010) 0.90
Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. Alzheimers Res Ther (2013) 0.89
Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test (2008) 0.89
Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun (2009) 0.87
A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimers Dement (2014) 0.87
Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag (2013) 0.86
Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet. Neurology (2014) 0.85
Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag (2015) 0.84
To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk. Genet Test Mol Biomarkers (2012) 0.83
Nocebo and the potential harm of 'high risk' labelling: a scoping review. J Adv Nurs (2015) 0.83
The ethics of disclosing genetic diagnosis for Alzheimer's disease: do we need a new paradigm? Br Med Bull (2011) 0.80
Emotional responses to APO E genotype disclosure for Alzheimer disease. J Genet Couns (2005) 0.79
To test or not to test: interest in genetic testing for Alzheimer's disease among middle-aged adults. Am J Alzheimers Dis Other Demen (2003) 0.76
Associations between self-referral and health behavior responses to genetic risk information. Genome Med (2015) 0.76